The U Preventive Services Task Forc...

The U Preventive Services Task Force (USPSTF), a nonfederal, independent panel of scientists with notable experience in primary care and evidence-based medicine, is conven and supported by dint of the Agency for Healthcare Research and Quality and charged at Congress to develop evidence-based recommendations for the health care community. These recommendations generally are aimed at primary care physicians, who deliver a range of preventive services to asymptomatic ones in a typical ambulatory practice setting.

In 2004 the USPSTF issued pair recommendations (1) on screening for hepatitis C virus (HCV) infection: a recommendation against routine screening for HCV infection in asymptomatic adults who are not at increased risk (grade D recommendation), and a finding of insufficient evidence to commit for or against routine screening for HCV infection in adults at high risk (grade I recommendation). The latter recommendation has elicited one controversy, and it may be useful to clarify the reasoning behind the recommendation.

The USPSTF examines the evidence for the impact of screening and associated interventions forward both favorable and adverse health issues then weighs the benefits and harms to arrive at a without deductions health benefit at the population horizontal to assist the physician who makes decisions at the individual of the same height Recommendations with A, B, C and D grades meditate net health benefits that are (respecively) substantial, moderate, small, and none. Grade I mirrors substantial gaps in available evidence as it was that the USPSTF is unable to assess the clear health benefit; therefore, it is a call for further research to clarify the clear health benefit. (2)

When the natural history of a disease is known and the relationship of intermediate issue measures (e.g., biochemical marker flushs disease stage, viral titers) and health consequence measures (e.g., morbidity and mortality rates) is well established, improvement in intermediate consequences is a valid surrogate measure for improvement in health consequences However, the natural history of HCV infection is not well described in the literature. The great majority of bodys infected with HCV apparently do not progres to cirrhosis, with no other than 10 to 20 percent of infected someones developing cirrhosis after 20 to 30 years of infection. (34) generally no method can reliably predict which patients will progres to cirrhosis. In the absence of the ability to target therapy to patients who ne it, treating all HCV-infected ones would be worthwhile only if the treatment has proven benefit in reducing or preventing disease progression to cirrhosis or cancer, and if the treatment has minimal or no adverse drifts In addition, the maximal potential public health benefit would be reduc if all HCV-infected patients do not receive or rejoin to treatment. Factors influencing treatment eligibility and answer rates include severity of liver damage, active alcohol abuse, illicit medicine use, and other serious physical or psychologic comorbidities.

A review (3) of the available evidence in succession HCV infection shows that solitary 30 to 40 percent of infected bodily substances who are referred for treatment are eligible to receive it, and that sole 54 to 60 percent of treated patients have sustained reduc viremia. The duration of this reply beyond the length of the rife studies (i.e., a few years) is not known. most numerous importantly, the efficacy of treatment in reducing or preventing disease progression to cirrhosis has not been established. Adverse efficiencys are experienced by 50 to 60 percent of treated patients; these issues are severe enough for up to 22 percent of patients who receive combination therapy with pegylated interferon and ribavirin to discontinue treatment.3 Additional harms are associated with the diagnostic work-up (eg complications from liver biopsy) and screening (eg psychologic harms like as anxiety, negative effects forward partner relationships). The magnitude of harms of screening is unclear.

It is not known whether counseling HCV-infected individuals to change their behavior decreases rates of disease transmission or if it leads to improved health consequences There is no evidence showing that vaccination against hepatitis A virus or counseling against alcohol use in HCV-infected living bodys leads to reduced rates of cirrhosis. Although there may be other reasons to advocate HCV testing (eg disease surveillance, research, disease management in individual patients), it does not alter the fact that in succession the basis of proven health benefit to individual patients, the evidence to support screening is insufficient. Primary care physicians have limited time and resources to deliver preventive services. The USPSTF believes that services with adequate evidence for substantial to moderate snare health benefit (grades A and B) should receive the highest priority for delivery. After delivering these services, physicians can decide in what way to prioritize other interventions. This strategy would be rely uponed to yield the greatest health benefit to individual patients and to the entire population while making the chiefly prudent use of time and resources.